This text argues that generic usage, mandatory rebates to Medicare, budgetary caps on premiums, price controls, and a top-down cost-containment approach could delay introduction of drugs, cost US jobs and raise prices.
Read More
This text argues that generic usage, mandatory rebates to Medicare, budgetary caps on premiums, price controls, and a top-down cost-containment approach could delay introduction of drugs, cost US jobs and raise prices.
Read Less
